CJC-1295 (Mod GRF 1-29) & Ipamorelin & GHRP-2 Blend (9mg) – Triple-Action GH Research Peptide

Welcome to Liaocheng Yixin Company, your trusted source for premium cjc-1295 ipamorelin ghrp-2 blend 9mg for research. As a specialized peptide synthesis manufacturer operating from our facility at No. 9 Lushan Road, Dongchengcjc-1295 ipamorelin ghrp-2 blend 9mg for research Street, Liaocheng Economic and Technological Development Zone, Shandong Province, we provide high-quality research compounds for the global scientific community.  

This 9mg triple blend combines CJC-1295 (without DAC, also known as Modified GRF 1-29) with two mechanistically distinct ghrelin receptor agonists—Ipamorelin and GHRP-2. The formulation is designed to maximize growth hormone release through concurrent triple-pathway activation of pituitary somatotrophs . CJC-1295 provides the GHRH-receptor input, driving cAMP/PKA-mediated GH gene transcription, while Ipamorelin and GHRP-2 both activate GHS-R1a but differ substantially in their downstream consequences . Our cjc-1295 ipamorelin ghrp-2 blend 9mg for research offers investigators a convenient, precisely formulated tool for endocrine signaling, receptor pharmacology, and growth hormone axis studies.

What is the CJC-1295, Ipamorelin & GHRP-2 Blend?

This 9mg lyophilized blend contains three research peptides that work through complementary mechanisms :

CJC-1295 without DAC is a tetrasubstituted GHRH analog with four amino acid substitutions at positions 2, 8, 15, and 27 that protect it from rapid enzymatic degradation, extending its half-life from approximately 7 minutes (native GHRH) to roughly 30 minutes . Ipamorelin is a pentapeptide ghrelin mimetic known for its highly selective GH release with minimal stimulation of cortisol or prolactin . GHRP-2 (pralmorelin) is a potent hexapeptide that provides robust GH output alongside measurable increases in ACTH, cortisol, and prolactin .

Mechanism of Action in Research

The blend combines three complementary growth hormone secretagogues that act through distinct but converging mechanisms at the hypothalamic-pituitary axis :

GHRH Receptor Pathway (CJC-1295)

CJC-1295 binds the GHRH receptor (GHRHR) on anterior pituitary somatotrophs, activating Gs-coupled adenylyl cyclase signaling. This elevates intracellular cAMP, activates protein kinase A (PKA), and phosphorylates CREB to drive GH gene transcription and prime somatotroph secretory vesicles for exocytosis . The tetrasubstitution confers resistance to DPP-IV cleavage, extending the effective half-life compared to native GHRH .

GHS-R1a Pathway (Ipamorelin & GHRP-2)

Both Ipamorelin and GHRP-2 activate the growth hormone secretagogue receptor type 1a (GHS-R1a), the endogenous ghrelin receptor, on pituitary somatotrophs. This triggers Gq-coupled phospholipase C (PLC) signaling, generating IP3 and DAG, mobilizing intracellular calcium from the endoplasmic reticulum, and activating protein kinase C (PKC). The resulting calcium influx directly triggers GH vesicle exocytosis .

Complementary Mechanisms of GHRP-2

GHRP-2 provides additional hypothalamic-level effects not shared by Ipamorelin: it stimulates endogenous GHRH release from arcuate nucleus neurons and functionally suppresses somatostatin release from periventricular neurons . This dual hypothalamic action creates a permissive environment for maximal GH pulse amplitude. GHRP-2 also mildly stimulates ACTH, cortisol, and prolactin release—effects largely absent with the more selective Ipamorelin . cjc-1295 ipamorelin ghrp-2 blend 9mg for research

Triple Convergence

The combination produces GH output through at least three amplification mechanisms: (1) GHRH/ghrelin receptor synergy at the somatotroph level, as established by Bowers (1990); (2) GHRP-2-mediated suppression of somatostatin tone, removing the hypothalamic brake on GH release; and (3) potential complementary receptor occupancy dynamics from two structurally distinct GHS-R1a ligands . The combination of GHRH-pathway (cAMP/PKA) and ghrelin-pathway (PLC/PKC/Ca2+) activation produces synergistic GH release that substantially exceeds the sum of individual peptide effects, with AUC GH documented at 2 to 4 times higher compared to each compound as monotherapy .

Scientific Research Applications

Growth Hormone Secretagogue Research

This blend is studied for its ability to maximize GH output through concurrent triple-pathway activation. CJC-1295 provides sustained GHRH signaling while Ipamorelin and GHRP-2 trigger acute GH pulses through the ghrelin receptor . The triple combination maximizes synergy while GHRP-2’s somatostatin-suppressing action extends the secretory window .

Selectivity and Receptor Bias Studies

The two GHS-R1a ligands in this blend differ substantially in their downstream consequences: Ipamorelin produces highly selective GH release with negligible cortisol or prolactin elevation, while GHRP-2 generates robust GH output alongside measurable increases in ACTH, cortisol, and prolactin . This allows researchers to study the effects of different receptor engagement profiles.

Receptor Pharmacology

The combination of two GHS-R1a agonists is hypothesized to produce more complete receptor activation through potential differences in receptor binding kinetics, biased agonism profiles, and secondary target engagement . GHRP-2 additionally activates hypothalamic NPY/AgRP neurons involved in appetite regulation and has demonstrated immunomodulatory properties in research models . cjc-1295 ipamorelin ghrp-2 blend 9mg for research

Body Composition and Recovery Research

GH pulse amplitude is a key determinant of downstream effects including IGF-1 elevation, protein synthesis stimulation, lipolysis, and collagen synthesis. Research in GH-deficient models demonstrates that pulsatile GH administration is more effective than continuous infusion for promoting lean body mass and reducing adiposity .

Why Choose Liaocheng Yixin Company?

When sourcing cjc-1295 ipamorelin ghrp-2 blend 9mg for research, quality and reliability are paramount. Here’s why researchers trust us:

Manufacturer-Direct Quality

We are a legitimate, licensed peptide synthesis company with a physical headquarters in Shandong Province, China. Our facility maintains strict quality control standards.

Verified Purity Standards

Every batch undergoes rigorous testing using HPLC analysis. Certificates of Analysis are available upon request.

Research-Grade Specifications

• Purity: ≥99% verified by HPLC

• Appearance: White lyophilized powder

• Storage: Store powder at -20°C in a sealed, desiccated container, protected from light and moisture

• Form: Lyophilized powder for research use

• cjc-1295 ipamorelin ghrp-2 blend 9mg for research

Quality Assurance & Testing

Every batch undergoes comprehensive quality control:

1. Synthesis by experienced chemists using solid-phase peptide synthesis

2. Purification via preparative HPLC

3. Analysis using HPLC for purity verification

4. Mass Spectrometry for molecular weight confirmation

5. Packaged in sterile conditions for research use

6. cjc-1295 ipamorelin ghrp-2 blend 9mg for research

: How does the CJC-1295, Ipamorelin & GHRP-2 blend work in research?

A: CJC-1295 activates the GHRH receptor on pituitary somatotrophs, while Ipamorelin and GHRP-2 both engage the GHS-R1a receptor through distinct signaling profiles . This triple pathway activation produces synergistic GH release through multiple amplification mechanisms: GHRH/ghrelin receptor synergy, GHRP-2-mediated suppression of somatostatin tone, and potential complementary receptor occupancy dynamics from two structurally distinct GHS-R1a ligands .

: What distinguishes Ipamorelin from GHRP-2 in this blend?

A: Ipamorelin produces highly selective GH release with negligible cortisol or prolactin elevation, while GHRP-2 generates robust GH output alongside measurable increases in ACTH, cortisol, and prolactin . GHRP-2 is approximately 25% more potent for raw GH release, but the cortisol and prolactin elevation is a key consideration for research designs .

: What are the key research applications for this triple blend?

A: This blend is used in growth hormone secretagogue research (synergy studies), receptor pharmacology and bias studies, body composition research, and investigations of GHRP-2’s broader hypothalamic effects including appetite regulation and immunomodulation .

: What purity level can I expect?

A: All batches are tested to ensure ≥99% purity by HPLC analysis. Certificates of Analysis are available upon request.

: Is this product for human use?

A: No. This triple blend is manufactured strictly for research use only (RUO). It is not intended for human consumption or clinical applications.

When you need premium cjc-1295 ipamorelin ghrp-2 blend 9mg for research for your endocrine, receptor pharmacology, or growth hormone axis studies, choose a manufacturer that prioritizes quality, transparency, and reliability. Liaocheng Yixin Company combines expert peptide synthesis capabilities with rigorous quality control to deliver research materials you can trust.  cjc-1295 ipamorelin ghrp-2 blend 9mg for research